Lipitor (Atorvastatin)

Atorvastatin is indicated for disorders of lipid metabolism and for reducing cardiovascular risk.

• Hypercholesterolemia: lowers LDL‑cholesterol to target levels.
• Mixed dyslipidemia: reduces total cholesterol, LDL‑C and triglycerides while modestly raising HDL‑C.
• Primary prevention of cardiovascular disease: decreases the incidence of myocardial infarction, stroke and related events in high‑risk patients.
• Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with established coronary artery disease.

• Atorvastatin competitively inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis. This inhibition reduces intracellular cholesterol, prompting up‑regulation of LDL receptors on hepatocytes, which accelerates clearance of circulating LDL‑cholesterol and modestly lowers VLDL and triglycerides.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Muscle pain (myalgia): aching or soreness without weakness.
• Abdominal discomfort: occasional stomach pain or dyspepsia.
• Nausea: transient feeling of queasiness.
• Constipation or diarrhea: changes in bowel habit.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with risk of renal failure.
• Elevated liver enzymes: indication of hepatic injury.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Myopathy with weakness: notable loss of strength.
• Acute pancreatitis: sudden abdominal pain with elevated enzymes.

Before initiating therapy, consider the following safety measures.

• Monitor liver function: obtain baseline and periodic ALT/AST tests.
• Assess muscle symptoms: advise patients to report unexplained muscle pain or weakness.
• Avoid use in active liver disease: contraindicated in patients with hepatic impairment.
• Adjust dose in renal impairment: use caution in patients with reduced kidney function.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Atorvastatin may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase statin exposure and risk of myopathy.
• Gemfibrozil: synergistic effect on muscle toxicity.
• Cyclosporine: raises atorvastatin plasma concentrations.

Moderate Interactions (Monitor Closely)

• Macrolide antibiotics (e.g., erythromycin): may modestly increase statin levels.
• Antacids containing aluminum or magnesium: can reduce oral absorption.
• Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring.